GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Proteome Sciences PLC (LSE:PRM) » Definitions » ROE % Adjusted to Book Value

Proteome Sciences (LSE:PRM) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Proteome Sciences ROE % Adjusted to Book Value?

Proteome Sciences's ROE % for the quarter that ended in Jun. 2024 was 0.00%. Proteome Sciences's PB Ratio for the quarter that ended in Jun. 2024 was N/A. Proteome Sciences's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was N/A.


Proteome Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Proteome Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteome Sciences ROE % Adjusted to Book Value Chart

Proteome Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity Negative Equity Negative Equity Negative Equity -

Proteome Sciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity Negative Equity - - -

Competitive Comparison of Proteome Sciences's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Proteome Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteome Sciences's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's ROE % Adjusted to Book Value falls into.


';

Proteome Sciences ROE % Adjusted to Book Value Calculation

Proteome Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Proteome Sciences's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteome Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Proteome Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteome Sciences Business Description

Traded in Other Exchanges
Address
Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is protein biomarker research and development. provider of contract research services for the identification, validation and application of protein biomarkers. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Other.